This study was designed to evaluate the platelet-inhibiting effect of a new drug, calcium dobesilate, and to compare its efficacy to the known antiplatelet agent, ibuprofen. Five centimeter long expanded polytetrafluoroethylene grafts (internal diameter 4 mm) were used to replace 48 carotid arteries in 24 dogs. Autologous platelets were labeled with indium-111-labeled tropolone and reinjected into each animal 24 hours before operation. Six animals received an intravenous placebo, six received 12.5 mg/kg of intravenous ibuprofen, six received 100 mg/kg of intravenous calcium dobesilate, and six received 200 mg/kg of intravenous calcium dobesilate before cross-clamping. The grafts were removed after 3 hours, and radioactivity was measured and platelet deposition calculated. The results have indicated that preoperative administration of ibuprofen and calcium dobesilate in this animal model significantly diminishes early platelet deposition. Calcium dobesilate appears to be a dose-dependent, highly effective antiplatelet agent.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/0002-9610(85)90443-x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Discovery of a potent, Kv7.3-selective potassium channel opener from a Polynesian traditional botanical anticonvulsant.
Commun Chem
October 2024
Bioelectricity Laboratory, Department of Physiology and Biophysics, School of Medicine, University of California, Irvine, CA, USA.
Plants remain an important source of biologically active small molecules with high therapeutic potential. The voltage-gated potassium (Kv) channel formed by Kv7.2/3 (KCNQ2/3) heteromers is a major target for anticonvulsant drug development.
View Article and Find Full Text PDFWhich dose of calcium dobesilate is more effective and safe in chronic venous insufficiency? Multicenter retrospective clinical trial.
Phlebology
September 2024
Department of Cardiovascular Surgery, Memorial Hospital, Ankara, Turkey.
Article Synopsis
- The study evaluated the effectiveness and safety of two dosages of calcium dobesilate (500 mg vs. 1000 mg) in patients with Chronic Venous Insufficiency (CVI) in CEAP classes C3-C4.
- A multicenter retrospective analysis monitored patient progress over 12 months, using scores and circumference measurements to gauge improvement.
- Results showed that the higher dosage (1000 mg) significantly improved symptom relief and reduced limb swelling compared to the lower dosage, indicating a potential benefit of using higher doses for managing advanced CVI.
Correction of negative-interference from calcium dobesilate in the Roche sarcosine oxidase creatinine assay using CuO.
Clin Chem Lab Med
January 2025
Clinical Laboratory, Minhang Hospital, 12478 Fudan University, Shanghai, Shanghai, China.
Study protocol for assessment of the efficacy of calcium dobesilate versus placebo on SARS-CoV-2 viral load in outpatients with COVID-19 (CADOVID study): a randomised, placebo-controlled, double-blind, monocentric phase II trial.
BMJ Open
May 2024
Division of Primary Care Medicine, Geneva University Hospitals, Geneva, Switzerland.
Introduction: SARS-CoV-2 mainly infects respiratory endothelial cells, which is facilitated through its spike protein binding to heparan sulphate. Calcium dobesilate (CaD) is a well-established, widely available vasoactive and angioprotective drug interacting with heparan sulphate, with the potential to interfere with the uptake of SARS-CoV-2 by epithelial cells. The CADOVID trial aims to evaluate the efficacy and safety of CaD in reducing the SARS-CoV-2 viral load in non-hospitalised adult patients diagnosed with COVID-19, confirmed by a positive SARS-CoV-2 PCR, including its efficacy to reduce the impact of persistent COVID-19 symptoms.
View Article and Find Full Text PDFAssessment of the Tolerance of Dobenox Forte in Patients with Chronic Venous Disease.
Life (Basel)
March 2024
Department of Physiotherapy, School of Health Sciences in Katowice, Medical University of Silesia in Katowice, 40-752 Katowice, Poland.
This prospective, observational, multicenter study assessed the tolerance of Dobenox Forte, the first approved over-the-counter product containing calcium dobesilate, in 1795 outpatients with chronic venous disease (CVD) in daily clinical practice. In addition, the effectiveness (decrease in circumferences of a more affected limb at the ankle and middle part of the calf, and changes in the severity of CVD signs) was assessed. No adverse events related to use of the preparation were reported in a period of 64 ± 20 days.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!